INTRODUCTION: Supratentorial primitive neuroectodermal tumors (SPNET) are rare tumors accounting for only 2.5% of childhood brain tumors. The purpose of this study was to describe the range of treatment regimens used to treat pediatric SPNET in Canada and to identify prognostic factors for overall survival in this population. METHODS: This study was a retrospective clinical analysis of SPNET patients treated over the last 10 years in Canada. A questionnaire was developed and distributed to all institutions in Canada who treat pediatric patients. Data were collected for patients <19 years of age who were diagnosed and treated for SPNET between 1995 and 2005. RESULTS: Data were obtained for 48 eligible patients. The stages of patients for whom complete data were provided were 80, 3, and 16% for metastatic stage M0, M1, and M2/3, respectively. The best responses to therapy included complete response in 44%, partial response in 8%, still on therapy in 2%, progressive disease in 31%, toxic death in 2%, and no therapy given in 12%. The 4-year survival was 37.7 +/- 7.6%. The factors associated with an increase in survival were the use of radiation therapy and chemotherapy, and age >2 years. Overall survival was not affected by metastatic disease at diagnosis, tumor site, or degree of initial resection. CONCLUSIONS: Survival is poor in SPNET patients but highest in those who received chemotherapy and radiation therapy. Further studies are needed to improve the survival of these patients.
INTRODUCTION: Supratentorial primitive neuroectodermal tumors (SPNET) are rare tumors accounting for only 2.5% of childhood brain tumors. The purpose of this study was to describe the range of treatment regimens used to treat pediatric SPNET in Canada and to identify prognostic factors for overall survival in this population. METHODS: This study was a retrospective clinical analysis of SPNET patients treated over the last 10 years in Canada. A questionnaire was developed and distributed to all institutions in Canada who treat pediatric patients. Data were collected for patients <19 years of age who were diagnosed and treated for SPNET between 1995 and 2005. RESULTS: Data were obtained for 48 eligible patients. The stages of patients for whom complete data were provided were 80, 3, and 16% for metastatic stage M0, M1, and M2/3, respectively. The best responses to therapy included complete response in 44%, partial response in 8%, still on therapy in 2%, progressive disease in 31%, toxic death in 2%, and no therapy given in 12%. The 4-year survival was 37.7 +/- 7.6%. The factors associated with an increase in survival were the use of radiation therapy and chemotherapy, and age >2 years. Overall survival was not affected by metastatic disease at diagnosis, tumor site, or degree of initial resection. CONCLUSIONS: Survival is poor in SPNET patients but highest in those who received chemotherapy and radiation therapy. Further studies are needed to improve the survival of these patients.
Authors: Barry L Pizer; Claire L Weston; Kathryn J Robinson; David W Ellison; James Ironside; Frank Saran; Linda S Lashford; Diana Tait; Helen Lucraft; David A Walker; Clifford C Bailey; Roger E Taylor Journal: Eur J Cancer Date: 2006-04-24 Impact factor: 9.162
Authors: L B Rorke; J Q Trojanowski; V M Lee; R A Zimmerman; L N Sutton; J A Biegel; J W Goldwein; R J Packer Journal: Brain Pathol Date: 1997-04 Impact factor: 6.508
Authors: R I Jakacki; P M Zeltzer; J M Boyett; A L Albright; J C Allen; J R Geyer; L B Rorke; P Stanley; K R Stevens; J Wisoff Journal: J Clin Oncol Date: 1995-06 Impact factor: 44.544
Authors: B H Cohen; P M Zeltzer; J M Boyett; J R Geyer; J C Allen; J L Finlay; P McGuire-Cullen; J M Milstein; L B Rorke; P Stanley Journal: J Clin Oncol Date: 1995-07 Impact factor: 44.544
Authors: Rachael A Lester; Lindsay C Brown; Laurence J Eckel; Robert T Foote; Amulya A NageswaraRao; Jan C Buckner; Ian F Parney; Nicholas M Wetjen; Nadia N Laack Journal: J Neurooncol Date: 2014-08-13 Impact factor: 4.130
Authors: Martin Mynarek; Barry Pizer; Christelle Dufour; Dannis van Vuurden; Miklos Garami; Maura Massimino; Jason Fangusaro; Tom Davidson; Maria Joao Gil-da-Costa; Jaroslav Sterba; Martin Benesch; Nicolas Gerber; B Ole Juhnke; Robert Kwiecien; Torsten Pietsch; Marcel Kool; Steve Clifford; David W Ellison; Felice Giangaspero; Pieter Wesseling; Floyd Gilles; Nicholas Gottardo; Jonathan L Finlay; Stefan Rutkowski; Katja von Hoff Journal: Neuro Oncol Date: 2017-04-01 Impact factor: 12.300
Authors: Regina I Jakacki; Peter C Burger; Mehmet Kocak; James M Boyett; Joel Goldwein; Minesh Mehta; Roger J Packer; Nancy J Tarbell; Ian F Pollack Journal: Pediatr Blood Cancer Date: 2015-02-19 Impact factor: 3.167